Lux Biosciences Receives FDA Clearance For LX211 IND
Wed, 29 Nov 2006 08:00 AM EST
... Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the 30- day waiting period for its Investigational New Drug Application (IND) for the development of LX211 in uveitis has elapsed, paving the way for initiation of pivotal clinical trials in early 2007. [click link for full article] ...
Related Topics
- Creatinine Clearance
- Creatinine
- Tacrolimus ointment
- Mammography
- Carcinogens
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Phosgene Oxime
- Thalidomide
- Food Labeling
- Drug Safety
- Yohimbe
- Food Labels
- Clinical Trials
- Celecoxib
- Carvedilol
- Tysabri
- Emergency Contraception
- Levonorgestrel Emergency Contraception
- Rofecoxib

Not Signed In -


